Cargando…

A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients

The anticancer immune response is shaped by immunogenic cell stress and death pathways. Thus, cancer cells can release danger-associated molecular patterns that act on pattern recognition receptors expressed by dendritic cells and their precursors to elicit an antitumor immune response. Here, we inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Naour, Julie, Sztupinszki, Zsofia, Carbonnier, Vincent, Casiraghi, Odile, Marty, Virginie, Galluzzi, Lorenzo, Szallasi, Zoltan, Kroemer, Guido, Vacchelli, Erika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037530/
https://www.ncbi.nlm.nih.gov/pubmed/35481288
http://dx.doi.org/10.1080/2162402X.2022.2059878
_version_ 1784693742632960000
author Le Naour, Julie
Sztupinszki, Zsofia
Carbonnier, Vincent
Casiraghi, Odile
Marty, Virginie
Galluzzi, Lorenzo
Szallasi, Zoltan
Kroemer, Guido
Vacchelli, Erika
author_facet Le Naour, Julie
Sztupinszki, Zsofia
Carbonnier, Vincent
Casiraghi, Odile
Marty, Virginie
Galluzzi, Lorenzo
Szallasi, Zoltan
Kroemer, Guido
Vacchelli, Erika
author_sort Le Naour, Julie
collection PubMed
description The anticancer immune response is shaped by immunogenic cell stress and death pathways. Thus, cancer cells can release danger-associated molecular patterns that act on pattern recognition receptors expressed by dendritic cells and their precursors to elicit an antitumor immune response. Here, we investigated the impact of single nucleotide polymorphisms (SNPs) in genes affecting this cancer-immunity dialogue in the context of head and neck squamous cell carcinoma (HNSCC). We observed that homozygosity for a loss-of-function SNP (rs2241880, leading to the substitution of a threonine residue in position 300 by an alanine) affecting autophagy related 16 like 1 (ATG16L1) is coupled to poor progression-free survival in platinum-treated HNSCC patients. This result was obtained on a cohort of patients enrolled at the Gustave Roussy Cancer Campus and was validated on an independent cohort of The Cancer Genome Atlas (TCGA). Homozygosity in rs2241880 is well known to predispose to Crohn’s disease, and epidemiological associations between Crohn’s disease and HNSCC have been reported at the levels of cancer incidence and prognosis. We speculate that rs2241880 might be partially responsible for this association.
format Online
Article
Text
id pubmed-9037530
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-90375302022-04-26 A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients Le Naour, Julie Sztupinszki, Zsofia Carbonnier, Vincent Casiraghi, Odile Marty, Virginie Galluzzi, Lorenzo Szallasi, Zoltan Kroemer, Guido Vacchelli, Erika Oncoimmunology Original Research The anticancer immune response is shaped by immunogenic cell stress and death pathways. Thus, cancer cells can release danger-associated molecular patterns that act on pattern recognition receptors expressed by dendritic cells and their precursors to elicit an antitumor immune response. Here, we investigated the impact of single nucleotide polymorphisms (SNPs) in genes affecting this cancer-immunity dialogue in the context of head and neck squamous cell carcinoma (HNSCC). We observed that homozygosity for a loss-of-function SNP (rs2241880, leading to the substitution of a threonine residue in position 300 by an alanine) affecting autophagy related 16 like 1 (ATG16L1) is coupled to poor progression-free survival in platinum-treated HNSCC patients. This result was obtained on a cohort of patients enrolled at the Gustave Roussy Cancer Campus and was validated on an independent cohort of The Cancer Genome Atlas (TCGA). Homozygosity in rs2241880 is well known to predispose to Crohn’s disease, and epidemiological associations between Crohn’s disease and HNSCC have been reported at the levels of cancer incidence and prognosis. We speculate that rs2241880 might be partially responsible for this association. Taylor & Francis 2022-04-17 /pmc/articles/PMC9037530/ /pubmed/35481288 http://dx.doi.org/10.1080/2162402X.2022.2059878 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Le Naour, Julie
Sztupinszki, Zsofia
Carbonnier, Vincent
Casiraghi, Odile
Marty, Virginie
Galluzzi, Lorenzo
Szallasi, Zoltan
Kroemer, Guido
Vacchelli, Erika
A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients
title A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients
title_full A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients
title_fullStr A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients
title_full_unstemmed A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients
title_short A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients
title_sort loss-of-function polymorphism in atg16l1 compromises therapeutic outcome in head and neck carcinoma patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037530/
https://www.ncbi.nlm.nih.gov/pubmed/35481288
http://dx.doi.org/10.1080/2162402X.2022.2059878
work_keys_str_mv AT lenaourjulie alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT sztupinszkizsofia alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT carbonniervincent alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT casiraghiodile alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT martyvirginie alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT galluzzilorenzo alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT szallasizoltan alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT kroemerguido alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT vacchellierika alossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT lenaourjulie lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT sztupinszkizsofia lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT carbonniervincent lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT casiraghiodile lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT martyvirginie lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT galluzzilorenzo lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT szallasizoltan lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT kroemerguido lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients
AT vacchellierika lossoffunctionpolymorphisminatg16l1compromisestherapeuticoutcomeinheadandneckcarcinomapatients